FDA doubles initial Evusheld dosing regimen to enhance prevention of COVID-19 variants

The FDA has revised its emergency use authorization for the monoclonal antibody cocktail Evusheld, doubling its initial dosing for COVID-19 prevention in light of data suggesting it may be less active against certain omicron subvariants.
The authorized initial dose for Evusheld (tixagevimab plus cilgavimab, AstraZeneca) is now 300 mg of tixagevimab and 300 mg of cilgavimab, increased from the previous authorization of 150 mg for each.
Patients who have already received the previously authorized dose should receive an additional 150 mg dose of tixagevimab and cilgavimab each “as soon as

The FDA has revised its emergency use authorization for the monoclonal antibody cocktail Evusheld, doubling its initial dosing for COVID-19 prevention in light of data suggesting it may be less active against certain omicron subvariants.
The authorized initial dose for Evusheld (tixagevimab plus cilgavimab, AstraZeneca) is now 300 mg of tixagevimab and 300 mg of cilgavimab, increased from the previous authorization of 150 mg for each.
Patients who have already received the previously authorized dose should receive an additional 150 mg dose of tixagevimab and cilgavimab each “as soon as